BiCAR: what clinicians are saying
glofitamab plus obinutuzumab in relapsed/refractory diffuse large B-cell lymphoma after CAR-T therapy · NCT04703686 ↗ · Phase 2 · The Lymphoma Academic Research Organisation
BiCAR was favored in unattributed remarks for reducing delays to full-dose treatment, an argument about urgency rather than a claim of greater benefit from acceleration. A speaker describing a separate high-risk cohort considered accelerated glofitamab feasible but attributed less benefit and more toxicity to adverse patient features. That experience warrants caution about extending use rather than contradicting the trial’s safety findings; the speaker called for studies to identify who would benefit.
Created with AI · how we check it
- edition 1
- commentary checked Nov 17, 2026
- 68 verified statements
3 findings, and what sits behind each
01. Accelerated RO7082859 ramp-up: what speakers say
No named clinician · accounts and unnamed speakers · 18 statements from 1 speaker in 4 sources, 2 of them podcasts or videos · 10 passages
Limitations recorded: 3.
Draws on: Safety and tolerability, Population and setting.
02. RO7082859 after CAR-T: a speaker welcomes its activity, but says work remains
No named clinician · accounts and unnamed speakers · 21 statements from 2 speakers in 5 sources, 1 of them a podcast or video · 13 passages
Limitations recorded: 5.
Draws on: Population and setting, The comparison, Secondary endpoints, Safety and tolerability, Design and conduct.
Beyond the trial population
03. Fast ramp-up in high-risk DLBCL: a speaker finds it feasible but asks who benefits
No named clinician · accounts and unnamed speakers · 15 statements from 1 speaker in 2 sources, 1 of them a podcast or video · 4 passages
Limitations recorded: 5.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 3
No named clinician · accounts and unnamed speakers
Accelerated RO7082859 ramp-up: what speakers say
18 statements from 1 speaker in 4 sources, 2 of them podcasts or videos
- 18
- statements
- 10
- passages
- 4
- sources
- 1
- speaker
What the statements areViews 7Questions and uncertainty 2Clinical experience 2Comparisons 3Restated results and context 4Statement-to-passage links (a passage can back several statements)Supporting a statement 18Giving context 3Recorded with the findingLimitations: 3
2 podcasts and video · 2 publications
Draws on: Safety and tolerability, Population and setting.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
1 of the 3 findings and 9 of the 68 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (5)
CAR-T, chimeric antigen receptor T-cell therapy; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; OS, overall survival.
The full BiCAR report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
By the numbers
- 7commentary sources screened
- 6sources cited by verified statements
- 3named in screened sources
- 3speakers cited in the report
- 1cited speaker with a verified identity
0 cited clinicians, speakers with a confirmed clinical role, of them 0 physicians.
- 68verified statements, each linked to its source
- 0of them from speakers with a confirmed clinical role
- 3findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 3 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 68 | Paid |
| Who said each statement: the cited speakers | 3 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 0 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 1 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 9 | Free |
| Sources with links | 6 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
8 discussed · 1 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Overall Survivalno commentary found | 0 | 0 |
| Secondary endpoints | 2 | 1 |
| Population and setting | 4 | 4 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 3 | 1 |
| Safety and tolerability | 3 | 2 |
| Design and conduct | 2 | 1 |
| Accelerated ramp-up, treatment urgency and its unproven incremental benefit | 7 | 2 |
| Translation to high-risk, physician-selected practice | 11 | 1 |
| Bridging before CAR-T or transplantation | 2 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
68 verified statements from 6 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 23 statements · 34% | ||||
| YouTube | 23 | 2 | 2 | |
| Posts · 4 statements · 6% | ||||
| X threads | 2 | 1 | 4 | |
| LinkedIn posts | 2 | 1 | 1 | |
| Primary sources · 41 statements · 60%cited for context, not screened | ||||
| Publications | 41 | 2 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 2 / quarter
- Screened window
- Jun 2, 2021 → Jun 12, 2026
- Cited window
- Jun 2, 2021 → Dec 9, 2025
- Retrieved
- Nov 16, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
- Registry
- NCT04703686
- Study IDs
- BiCAR
- Sponsor
- The Lymphoma Academic Research Organisation
- Design
- Phase 2 · Interventional, single group
- Status
- Completed
- Enrollment
- 67 actual
- Registered
- 2021-01-11
- Start
- 2021-03-30 actual
- Primary completion
- 2023-01-10 actual
- Primary endpoint
- Overall Survival
- Interventions
- 2 registered
More on: Diffuse large B-cell lymphoma, obinutuzumab, glofitamab
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on accelerated glofitamab dose escalation and cytokine release syndrome risk in relapsed or refractory lymphoma.
- 10 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 51 sources about other trials or topics are not included; discussion that refers to the trial only by a name it shares with other things may be missing.
- Most substantive IACH remarks cannot be assigned to a named participant. They cannot be counted as additional independent speakers alongside named participants; Sarkozy's identifiable contribution is a brief affirmation.
Show all 11 known gaps +Fewer −
- The social-media statements include relayed material. They do not establish the relayers' independent endorsement, and reposts do not establish additional clinical agreement.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The mixed-histology ASH23 abstract summary, published DLBCL cohort and separate high-risk practice cohort are different populations. Their response, survival and toxicity figures should not be combined.
- Schedule descriptions differ across the panel, interview and publication. A full protocol and an exact regulatory label for the RO7082859 alias were not available for this edition, limiting independent reconciliation.
- The social-media posts and recordings reviewed do not directly assess BiCAR's own OS estimate or the choice of OS as the primary endpoint. The publication's treatment preference and methodological arguments are contextual interpretations, not evidence of independent HCP consensus.
- The external-control comparison does not establish causality or superiority over an individual salvage regimen or another bispecific; residual confounding and eligibility restrictions remain material.
How reports are built and checked: Methods.
Editions and corrections
Routine maintenance: 2 fixes (tags)
None of these changed a statement, finding or source.
- Nov 17, 2026 UTCtaxonomy mapping corrected
- Nov 17, 2026 UTCtaxonomy mapping corrected
Last checked for new commentary Nov 17, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. BiCAR (NCT04703686): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 17, 2026. https://www.erudio.com/reports/bicar-nct04703686
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "BiCAR" (NCT04703686), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "bicar-nct04703686". If you cannot make requests, read https://www.erudio.com/reports/bicar-nct04703686.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT04703686", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT04703686 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/bicar-nct04703686.json
curl https://www.erudio.com/reports/bicar-nct04703686.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "bicar-nct04703686" })release c3337248fe54d1fb8fe75f1be4f1de4d820d44bd8c9c20aa21ce31600c484391
Questions
How much does the BiCAR report cost?
This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.
What does the BiCAR report cover?
68 statements from 6 sources (2 videos, 2 posts, 2 papers), each linked to its source. Commentary checked Nov 17, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the BiCAR report?
Its preview, yes: get_report_card({ "slug": "bicar-nct04703686" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. Connect your AI client.
How current is the BiCAR report?
Edition 1 (version 1.0.0), accepted Nov 17, 2026 UTC; last checked for new commentary Nov 17, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.